NEW YORK — Swiss diagnostics company Proteomedix said Monday that it has signed a licensing agreement with Laboratory Corporation of America for its Proclarix prostate cancer test.
Under the agreement, Labcorp has the exclusive US rights to develop and commercialize the test, which measures the levels of several proteins, including prostate-specific antigen (PSA), in patient serum to determine the risk of clinically significant prostate cancer in men with elevated PSA.
Zurich-based Proteomedix announced in April that the test has been included in the 2023 guidelines for both the American Urological Association and the European Association of Urology.
"There is an important unmet medical need for an accurate diagnosis of clinically significant prostate cancer by employing an innovative, simple blood test," Proteomedix CEO Helge Lubenow said in a statement. "The future commercialization of this assay in the US will significantly impact how care and treatment for men with elevated PSA is managed."
"Labcorp is focused on expanding access to innovative diagnostic options like Proclarix," Prasanth Reddy, senior VP and oncology head at Labcorp, said in a statement. "This test will give patients and providers clear answers to help them make more informed decisions about the most appropriate monitoring and treatment plan for each patient."
Financial and other terms of the agreement were not disclosed.